Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Acne Inversa Clinical Trials

A listing of Acne Inversa medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (25) clinical trials

Hidradenitis Suppurativa (HS) is a chronic skin disease that causes painful bumps under the skin in areas like the underarms and groin. The bumps can often become inflamed, progress to abscess formation, and may rupture. Local physicians are currently evaluating a study medication for those who suffer from moderate to …

Phase N/A

Hidradenitis Suppurativa (HS) is a chronic skin disease that causes painful bumps under the skin in areas like the underarms and groin. The bumps can often become inflamed, progress to abscess formation, and may rupture. Local physicians are currently evaluating a study medication for those who suffer from moderate to …

Phase N/A

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety …

Phase N/A

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Phase

Tofacitinib for Immune Skin Conditions in Down Syndrome

Trisomy 21 (T21) is the most common human chromosomal disorder, occurring in ~1/700 live births, leading to the condition known as Down syndrome (DS). Importantly, people with DS display widespread immune dysregulation and over half of adults with T21 are affected by one or more autoimmune conditions, including several immune …

Phase

A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Phase

HidraWear AX HS Study

The objective is to evaluate the ease of use of Hidrawear AX compared to the subject's existing product use in 23 subjects with HS (Hidradenitis Suppurativa). Secondary objectives are to evaluate if Hidrawear AX: Is comfortable Improves quality of life Faster to use than the subject's existing product Reduces dressing …

Phase N/A

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two treatment periods. In Period A, participants are randomized to receive either risankizumab dose A, dose B, or placebo. In Period B, …

Phase

Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis

This study is an exploratory correlative study in subjects with HS or AD. Blood samples and skin biopsies will be collected from all subjects and used to assess the following: cutaneous and circulating inflammatory biomarkers and IRAK4 target levels in primary samples, correlations between cutaneous and circulating inflammatory biomarkers and …

Phase N/A

A Study to Evaluate the Safety and Efficacy of PF-06650833 PF-06700841 and PF 06826647 in Adults With Hidradenitis Suppurativa

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week …

Phase